Digestive Health Newsletter

Good Nutrition for a Bad Gut: Focus on Calcium, Vitamin D, and Bone Health

Colleen D Webb, MS, RD, CDN and Ellen J Scherl, MD, AGAF, FACG, FACP, FASGE

Volume 29, 
November 29, 2011

Make no bones about it

Nutritional deficiencies can be a problem for people living with inflammatory bowel disease (IBD), often due to the effects of inflammation on vitamin and mineral absorption and dietary restrictions. This newsletter focuses on calcium and vitamin D deficiencies and their impact on bone health. It also discusses steps you can take to promote strong bones.

Back to top

What is osteoporosis?

Osteoporosis means "porous bones" or a loss of bone tissue resulting in increased risk for fractures. Calcium and vitamin D play key roles in keeping your bones strong and healthy.

Back to top

Why are people with IBD at increased risk of osteoporosis?

An estimated 30% to 60% of people with IBD may have low bone density, putting them at risk for osteoporosis. This may be due to

  • Problems absorbing calcium and vitamin D

    Health conditions affecting the gastrointestinal tract can make it difficult to absorb enough nutrients. This is especially true if you have Crohn's disease, which commonly affects the small intestine where calcium and vitamin D are absorbed. If you have inflammation or have had surgery to bypass or remove parts of your small intestine then you may be at increased risk of calcium and vitamin D deficiencies. If you have ulcerative colitis, which primarily occurs in the large intestine, calcium and vitamin D absorption may be less of a problem.

  • Elevated cytokine levels

    Again, this is more likely an issue if you have Crohn's disease. Cytokines are proteins that increase inflammation in your body and also appear to slow the rate at which old bone is removed and new bone is formed.

  • Corticosteroid drugs

    If you take corticosteroid drugs (like prednisone) to treat IBD, you are at an increased risk of osteoporosis because corticosteroids interfere with calcium absorption. They also cause bone breakdown while preventing new bone from being formed. An estimated 30% to 50% of people who take corticosteroids for an extended period of time develop osteoporosis.

  • Lactose intolerance or sensitivity

    Some people with IBD can't tolerate dairy products because of lactose intolerance or sensitivity. This means that they cannot break down lactose, the main carbohydrate in milk. Since milk and other dairy products are good sources of calcium, this can contribute to a deficiency. Note that IBD does not increase your risk for lactose intolerance.

Back to top

Why is calcium important?

Bone may seem lifeless and inert, but it's actually living tissue. Your body is constantly breaking down old bone and creating new bone. Without adequate calcium intake and absorption, your body will take calcium from your bones, decreasing their mass and leading to osteoporosis. Since our bodies don't produce calcium, it's important to get enough from calcium-rich foods and/or supplements. Calcium is also critical for healthy teeth, proper nerve and muscle function, blood clotting, and hormone secretion.

Back to top

What about vitamin D?

It's also important to maintain adequate vitamin D levels. Vitamin D plays a key role in calcium absorption. A study of people with IBD found that those with low bone density also had a significantly higher rate of vitamin D deficiency, and those who increased their vitamin D levels also increased their bone density. Vitamin D may also play a role in regulating and strengthening your immune system and protecting against a number of chronic autoimmune diseases, including IBD.

Back to top

How is osteoporosis diagnosed?

Osteoporosis is typically diagnosed using special x-ray technology called dual energy x-ray absorptiometry (DEXA), a safe and painless test that measures the bone density in your spine, hip, and wrist (the areas most likely to be affected by osteoporosis). The DEXA test can detect osteoporosis before a fracture actually occurs and can predict your chances of having a fracture in the future. If you are being treated for osteoporosis, repeated tests can be used to monitor the effects of your treatment program.

You should be tested for osteoporosis if you are postmenopausal or have missed 3 menstrual periods in a row, are a female over age 50 or a male over age 70, have taken corticosteroids for more than 3 months, have had surgery on your small intestine, or have a history of low-trauma fracture. Once tested, you should repeat the DEXA every 2 years.

Discussing your 25-hydroxy vitamin D level with your physician is another way of monitoring bone health.

Back to top

What can I eat to help prevent and treat osteoporosis?

Research within the past decade has shown that increasing calcium and vitamin D intake can improve bone health in patients with IBD.

  • Calcium

    To increase your calcium intake, try low-fat dairy products or calcium-fortified foods and beverages, including soy, almond, and rice milk, as well as calcium-fortified juices and tofu made with calcium sulfate. If you have lactose intolerance, try aged cheeses and yogurt, which are usually well tolerated. Other good sources of calcium are canned sardines and salmon with bones, as well as green, leafy vegetables. Check out the recipes for Banana Oatmeal Parfait and Broccoli, Cannellini Bean, and Cheddar Soup. Both are great ways to boost your calcium.

    Recommended dietary allowances (RDAs) tell you how much calcium you need each day, as shown in Table 1.

    Table 1. Recommended Dietary Allowances (RDAs) for Calcium

    Ulcerative colitis diet information – Recommended dietary allowances for calcium

    *Adequate intake.

    Table 1. Recommended Dietary Allowances (RDAs) for Calcium

    Ulcerative colitis diet information – Recommended dietary allowances for calcium

    *Adequate intake.

  • Vitamin D

    Our bodies make vitamin D when our skin is directly exposed to the sun, and most people get at least some of the vitamin D they need this way. However, it may be difficult to get enough sun exposure if you have dark-colored skin, always wear sunscreen, are age 70 or older, or live in the northern part of the United States where the sun is not strong enough during the winter months. If that is the case, you can increase your intake by eating foods that contain significant amounts of vitamin D, such as fortified dairy products and orange juice; fatty fish like herring, mackerel, salmon, sardines, and tuna; and shitake mushrooms.

    The amount of vitamin D you need each day to promote optimal bone health depends on your age, as shown in Table 2. Recommended intakes are based on the assumption that you are getting little sun exposure.

    Table 2. Recommended Dietary Allowances (RDAs) for Vitamin D

    Ulcerative colitis diet information – Recommended dietary allowances for vitamin D

    *Adequate intake.

    Table 2. Recommended Dietary Allowances (RDAs) for Vitamin D

    Ulcerative colitis diet information – Recommended dietary allowances for vitamin D

    *Adequate intake.

Back to top

Boost your calcium with these recipes

Back to top

What else can I do to decrease my osteoporosis risk?

There are a number of other risk factors for developing osteoporosis, some of which you can't control (frame size, family history, being postmenopausal, and age) and some of which you can.

  • If you smoke, quit. Tobacco use contributes to weak bones and an increased risk of fractures by decreasing the amount of calcium your body absorbs. Additionally, women who smoke tend to go through earlier menopause, which decreases estrogen, a bone-preserving hormone

  • If you drink alcohol, do so in moderation. Regularly consuming more than 2 alcoholic drinks per day can interfere with your body's ability to absorb calcium. Heavy alcohol consumption is also usually accompanied by poor nutrition and an increased risk of falling and bone fracture

  • If you are sedentary, increase your physical activity. People with a sedentary lifestyle are more likely to develop osteoporosis. Physical activity, especially if it's weight bearing, helps strengthen your bones. Strengthening your muscles, improving your balance and flexibility, and preserving your joint mobility will also reduce your risk of falls

  • If you take medication that is associated with bone loss, talk to your doctor about other options. In addition to corticosteroids, medications like aromatase inhibitors, methotrexate, selective serotonin reuptake inhibitors, proton pump inhibitors, aluminum-containing antacids, and some antiseizure medications are all associated with increased osteoporosis risk

Back to top

What about calcium and vitamin D supplements?

Calcium supplements, like calcium carbonate or calcium citrate, can be a way to make sure you are getting enough calcium in your diet. Calcium carbonate is less expensive and best absorbed when taken with food. Calcium citrate can be taken either with food or on an empty stomach and is more easily absorbed in people with lower levels of stomach acid, such as older adults and people on proton pump inhibitors.

Regardless of the type of calcium supplement you take, absorption is best when you take no more than 500 mg at once. So if you need to take 1000 mg per day, try splitting the dose. If you find that your calcium supplement causes gas, bloating, and/or constipation, try taking it in a liquid or chewable form, spread throughout the day, and/or with food.

Vitamin D supplements come in 2 different forms that appear to be equivalent: D2 (ergocalciferol) and D3 (cholecalciferol). Both increase the amount of vitamin D in the blood.

Back to top

The bottom line

When you have IBD, it's important to be an active participant in maintaining your bone health. Be sure to discuss any concerns with your physician or nutritionist, and remember that early intervention can help you reverse bone loss before osteoporosis becomes a problem.

Back to top

If you found this article interesting, you may also be interested in our previous Your Digestive Health newsletters:

Have a great new year and look forward to more Your Digestive Health newsletters in 2012!

About the authors
Colleen D Webb

Colleen D Webb, MS, RD, CDN

Colleen Webb is the Clinical Nutritionist at the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medical College in New York City. She is a member of the Medical Advisory Committee of the Crohn's and Colitis Foundation of America (New York chapter) as well as an active member of the American Dietetic Association and the Greater New York Dietetic Association. She presents frequently on nutrition and IBD at IBD support groups throughout New York City. Ms Webb holds a Master of Science degree in Clinical Nutrition and Dietetics from New York University and a Bachelor of Arts degree from the University of Florida. Before joining the Jill Roberts Center for Inflammatory Bowel Disease, she provided medical nutrition therapy to veterans at the James J Peters VA Medical Center in the Bronx.

Ellen J Scherl

Ellen J Scherl, MD, AGAF, FACG, FACP, FASGE

Dr Scherl is Director of Research at the Jill Roberts Center for Inflammatory Bowel Disease, the Jill Roberts Associate Professor of Medicine at Weill Medical College of Cornell University/New York-Presbyterian Hospital in New York, and Adjunct Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Her current interests encompass investigational therapies for ulcerative colitis and Crohn's disease. Dr Scherl is an editorial reviewer for Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Gastrointestinal Endoscopy, and Gastroenterology and Hepatology. She has extensive experience in many clinical trials and has coauthored or coedited a number of publications. She also lectures frequently on IBD at local, regional, and national meetings.

About the authors
Colleen D Webb

Colleen D Webb, MS, RD, CDN

Dr Webb is the Clinical Nutritionist at the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medical College in New York City. She is a member of the Medical Advisory Committee of the Crohn's and Colitis Foundation of America (New York chapter) as well as an active member of the American Dietetic Association and the Greater New York Dietetic Association. She presents frequently on nutrition and IBD at IBD support groups throughout New York City. Dr Webb holds a Master of Science degree in Clinical Nutrition and Dietetics from New York University and a Bachelor of Arts degree from the University of Florida. Before joining the Jill Roberts Center for Inflammatory Bowel Disease, she provided medical nutrition therapy to veterans at the James J Peters VA Medical Center in the Bronx.

Ellen J Scherl

Ellen J Scherl, MD, AGAF, FACG, FACP, FASGE

Dr Scherl is Director of Research at the Jill Roberts Center for Inflammatory Bowel Disease, the Jill Roberts Associate Professor of Medicine at Weill Medical College of Cornell University/New York-Presbyterian Hospital in New York, and Adjunct Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Her current interests encompass investigational therapies for ulcerative colitis and Crohn's disease. Dr Scherl is an editorial reviewer for Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Gastrointestinal Endoscopy, and Gastroenterology and Hepatology. She has extensive experience in many clinical trials and has coauthored or coedited a number of publications. She also lectures frequently on IBD at local, regional, and national meetings.

About the authors
Colleen D Webb

Colleen D Webb, MS, RD, CDN

Dr Webb is the Clinical Nutritionist at the Jill Roberts Center for Inflammatory Bowel Disease at Weill Cornell Medical College in New York City. She is a member of the Medical Advisory Committee of the Crohn's and Colitis Foundation of America (New York chapter) as well as an active member of the American Dietetic Association and the Greater New York Dietetic Association. She presents frequently on nutrition and IBD at IBD support groups throughout New York City. Dr Webb holds a Master of Science degree in Clinical Nutrition and Dietetics from New York University and a Bachelor of Arts degree from the University of Florida. Before joining the Jill Roberts Center for Inflammatory Bowel Disease, she provided medical nutrition therapy to veterans at the James J Peters VA Medical Center in the Bronx.

Ellen J Scherl

Ellen J Scherl, MD, AGAF, FACG, FACP, FASGE

Dr Scherl is Director of Research at the Jill Roberts Center for Inflammatory Bowel Disease, the Jill Roberts Associate Professor of Medicine at Weill Medical College of Cornell University/New York-Presbyterian Hospital in New York, and Adjunct Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Her current interests encompass investigational therapies for ulcerative colitis and Crohn's disease. Dr Scherl is an editorial reviewer for Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Gastrointestinal Endoscopy, and Gastroenterology and Hepatology. She has extensive experience in many clinical trials and has coauthored or coedited a number of publications. She also lectures frequently on IBD at local, regional, and national meetings.

Back to top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

SWB 11/09

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter